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Abstract 
Objective: Osteoarthritis (OA) is a musculoskeletal disease which contributes to severe morbidity. The 
monosodium iodoacetate (MIA) rodent model of OA is now well established, however the effect of MIA on 
surrounding tissues post injection has not been investigated and as such the impact on phenotypic 
development is unknown. The aim of this investigation was to examine the impact of MIA incubation on 
skeletal muscle cells in vitro, to provide an indication as to the potential influence of MIA administration of 
skeletal muscle in vivo.  Methods: C2C12 skeletal muscle myotubes were treated with either 4.8μM MIA or 
10μM Dexamethasone (DEX, positive atrophic control) up to 72hrs post differentiation and sampled for 
morphological and mRNA analyses. Results: Significant morphological effects (fusion index, number of 
myotubes and myotube width, p<0.05) were evident, demonstrating a hypertrophic phenotype in control 
(CON) compared to a hyperplasic phenotype in MIA and DEX. Increases in MAFbx mRNA were also evident 
between conditions, with post-hoc analysis demonstrating significance between CON and DEX (p<0.001), but 
not between CON and MIA (p>0.05). Conclusions: These data indicate a significant impact of both DEX and 
MIA on regeneration and hypertrophy in vitro and suggest differential activating mechanisms. Future 
investigations should determine whether skeletal muscle regeneration and hypertrophy is affected in the in 
vivo rodent model and the potential impact this has on the OA phenotypic outcome. 
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1. Introduction 
Osteoarthritis (OA) is a debilitating musculoskeletal disease and presents a significant clinical problem in 
aging populations. OA manifests with pathological features including articular cartilage degradation, synovial 
inflammation, osteophyte formation and bone marrow lesions [1]. As the aetiology of OA is yet to be fully 
elucidated, in vivo pre-clinical animal models, which display comparable features to human OA, are 
particularly important in the basic and interventional research to understand disease onset, progression and 
potential therapeutic strategies [2].  
One such model is the rodent mono-sodium iodoacetate (MIA) model of OA [3], which is now extensively 
published in the literature. Upon injection into the intra-articular space of rodent knee joints, MIA causes 
rapid articular cartilage damage and degeneration, leading to the development of an arthritic phenotype. The 
histopathology including cartilage lesion developments and proteogylcan matrix loss, along with functional 
joint impairment have all been shown to present in similar capacities to human OA [4–6]. Despite being an 
established pre-clinical in vivo model of OA, there is a paucity of research investigating the physiological 
implications of MIA administration on surrounding musculoskeletal tissues. Although MIA is injected into the 
avascular intra-articular space; as a small cell permeable molecule MIA has the potential to diffuse across the 
synovium initiating its direct interaction with other musculoskeletal tissues.  
Skeletal muscle, of critical importance in OA pathology, plays an essential role in the stability of a joint when 
loading [7], and has been shown to directly regulate cartilage gene expression of collagen II and collagen IX 
proteins in vitro [8]. Furthermore, it is now clear that skeletal muscle size and strength contribute to a reduced 
risk of developing knee OA [9] and that skeletal muscle weakness and atrophy contribute to OA development 
and phenotype [10,11], particularly following previous musculoskeletal injury and arthroplasty [12]. 
Additionally, data suggest that quadriceps muscle weakness contributes to changes in key anabolic and 
catabolic matrix-regulating mRNA’s within key structural tissues of the joint (patellar tendon, medial and 
lateral collateral ligament, and medial and lateral meniscus [13]), indicating significant tissue interaction 
within the musculoskeletal system. 
It is of paramount importance that debilitating changes in skeletal muscle phenotypes observed in pre-clinical 
animal models are entirely representative of the unloading/disuse/dysfunction associated with in vivo OA 
pathology, if such models are to have utility in understanding OA as an integrated musculoskeletal disease. As 
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such, the degree to which MIA affects the surrounding tissues upon injection warrants investigation, to 
provide evidence as to whether the observed phenotype is developed through other means beyond primary 
cartilage degeneration. To this end, the aim of the current investigation was to develop a proof-of-concept 
model to investigate the effect of MIA on skeletal muscle cells in vitro.   
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2. Materials and methods  
2.1. Cell culture 
C2C12 murine myoblasts (ECACC, Sigma, UK) were used for all experimentation, and cultured in T80 flasks 
(Nunc™, Fisher Scientific, UK) maintained in a humidified 5% CO2 incubator (HERAcell 240i, Thermo 
Fisher, UK). Cells were maintained in growth media (GM) consisting of high glucose DMEM (Fisher 
Scientific) supplemented with 20% FBS (Dutscher Scientific, UK), 100U/ml Penicillin and 100µg/ml 
Streptomycin (Fisher Scientific) until 80% confluent, at which point cells were enzymatically detached from 
the flasks for either further sub-culture or experimentation. All experiments were conducted using cells below 
passage 13.  
2.2. Experimental treatments 
Myoblasts were seeded into 6 well plates at a density of 10 × 104 cells/cm2 and cultured in GM until cells 
reached confluency. At this point cells were transferred to differentiation media (DM) consisting of high 
glucose DMEM (Fisher Scientific) supplemented with 2% Horse Serum (Dutscher Scientific), 100U/ml 
Penicillin and 100µg/ml Streptomycin (Fisher Scientific) for 72hrs to induce myotube formation. After 72hrs 
in DM and following 4hrs serum starvation, myotubes were treated with 10μM Dexamethasone (DEX, 
atrophic control) or 4.8μM MIA or control (CON) media over a time-course of 0, 6, 24 and 48hrs. A 
preliminary experiment was conducted to investigate a dose of MIA that would elicit an atrophic and 
myogenic response, without causing overt cell death (data not shown). Cells were fixed for morphological 
analyses and harvested for protein and PCR assays at the experimental time-points defined. Time point 0hrs 
was defined as 30min post transfer to experimental conditions.  
2.3. Protein and mRNA analyses 
For assessment of total cellular protein content, protein was extracted using 0.2M Sodium Hydroxide and 
protein concentrations were determined using the Pierce™ 660 protein assay (Fisher Scientific), according to 
manufactures instructions. To investigate the expression of putative atrophic genes, RNA was extracted using 
the TRIzol method, according to the manufacturer’s instructions (Sigma). mRNA expression of MuRF-1 and 
MAFbx were analysed as previously described with slight modifications [14]. 10μL volume PCR assays were 
conducted using Quantifast One Step RT-PCR kit (Qiagen, UK) on a ViiA7TM Real-Time PCR System 
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(Applied bio-systems, Life Technologies). Data was analysed using the 2(-ΔΔCT) method using POLR2B as a 
housekeeping gene with all data calibrated to a single CON 0hrs sample.   
2.4. Fluorescence staining and microscopy 
At the designated time-point cells were fixed and stained using F-actin molecular probe Rhodamine Phalloidin 
(Life Technologies, Molecular Probes) and counterstained with DAPI to visualise nuclei. Images were 
captured using a Leica DM2500 Fluorescent microscope at 20x magnification and analyses were conducted 
using Image J software. 
2.5. Statistical analyses 
All data are presented as mean ± SD. Differences between experimental conditions throughout the time-
course investigated were analysed using a two-way ANOVA, using a Bonferroni Post-hoc test to analyse 
specific differences between isolated variables. All statistical analyses were conducted using SPSS version 
22.0.  
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3. Results  
3.1. MIA and DEX treatment affect myotube morphology 
Various myogenic and morphological parameters were analysed to investigate the effects of MIA and DEX. 
Investigations of fusion index revealed a significant statistical main effect for time (p<0.001, figure 1b), 
suggesting the cells continue to differentiate throughout the experimental time-course. Despite no main effect 
evident for condition (p=0.439), a significant interaction effect between condition and time was found 
(p=0.018, figure 1b). These data suggest there is differential fusion index between conditions throughout the 
time-course investigated, providing evidence that both MIA and DEX contribute to delayed but potentiated 
myoblast fusion compared to CON at 48hrs.  
Furthermore, significant main effects for time (p<0.001), condition (p<0.001) and an interaction effect 
(p<0.01, figure 1b) were evident for the number of myotubes. Post-hoc analyses demonstrated a greater 
number of myotubes present in both MIA and DEX conditions compared to CON (both p<0.001, figure 1b), 
with differences at 24hrs and 48hrs compared to 0hrs and 6hrs (all p<0.001, figure 1b). These data would 
suggest that both MIA and DEX contribute to a hyperplasic phenotype compared to CON, at the cost of 
reduced but more nucleated myotubes.  
To further investigate the effects of MIA on skeletal muscle cells, myotube width was analysed as an 
indication of the extent of hypertrophy following fusion. A significant main effect for condition (p<0.001, 
figure 1b) and approaching significant effect for time (p=0.078, figure 1b), with post-hoc analyses providing 
evidence that CON myotubes were significantly more hypertrophic than those in either MIA or DEX 
conditions (both p<0.001, figure 1b). This was supported by significant total cellular protein content data, 
whereby main effects for condition (p=0.034, figure 1b) and time (p<0.001, figure 1b) despite no interaction 
effect (p=0.94) were evident. Taking all these morphological data together, it would appear that MIA 
contributes to a hyperplasic phenotype compared to a hypertrophic phenotype observed in CON, similar to 
that evident in the positive atrophic DEX condition.  
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Figure 1. MIA induces significant morphological effects on skeletal muscle myotubes. (a) Cytochemical analyses 
demonstrate delayed regeneration and reduced hypertrophy in both DEX and MIA conditions compared to CON over a 
48 hr experimental time-course. Red = Phalloidin, Blue = DAPI, Scale bar = 50 µm. (b) Quantitative analyses of fusion 
index revealed a significant statistical main effect for time (*p<0.001), no main effect for condition (p=0.439) and a 
significant interaction effect between condition and time (***p=0.018). Significant main effects for time (*p<0.001), 
condition (**p<0.001) and an interaction effect (***p<0.01) were evident for the number of myotubes. A significant 
main effect for condition (*p<0.001) and approaching significant effect for time (p=0.078) were found for myotube 
width. Significant differences in total cellular protein with main effects for condition (*p=0.034) and time (**p<0.001) 
despite no interaction effect (p=0.94) were evident. 
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3.2. MuRF1 and MAFbx expression  
MuRF-1 and MAFbx are E3 ubiquitin ligases highly expressed in muscle wasting conditions and commonly 
used as markers of atrophy, due to their role in skeletal muscle protein breakdown. There was no effect of 
condition on the expression of MuRF1 mRNA (p = 0.517, figure 2a), despite an effect of time (p = 0.005, 
figure 2a), with no interaction effect.  Post-hoc analyses revealed a significant decrease in MuRF1 mRNA at 
48hrs compared to 6hrs (p = 0.003), with no differences between other time-points (p>0.05), suggesting early 
activation of this gene.  A significant increase in MAFbx was found between conditions (p<0.001, figure 2b), 
despite no effect of time (p = 0.902) or any interaction effect (p=0.353, figure 2B). Post-hoc analyses 
demonstrated no differences between CON and MIA (p = 0.678) in MAFbx mRNA expression, despite 
significant increases in the expression of this gene in DEX compared to both CON and MIA conditions (both 
p<0.001 figure 2b). These data together suggest there is transcriptional activation of a component of the 
ubiquitin proteasome system in the DEX condition, which may in part be responsible for the reduced myotube 
width. In contrast, it appears that MIA treatment at the experimental time-points investigated fails to activate 
the ubiquitin proteasome system, and the reduced myotube width in this condition may be mediated through a 
different pathway. 
  
Figure 2. mRNA expression of members of the ubiquitin proteasome system. (a) No effect of condition on the expression 
of MuRF1 mRNA (p = 0.517), despite an effect of time (*p = 0.005), with no interaction effect.  (b) A significant 
increase in MAFbx was found between conditions (**p<0.001, figure 2b), despite no effect of time (p = 0.902) or any 
interaction effect (p=0.353, figure 2b). 
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4. Discussion 
Animal models serve as important tools in understanding the basic aetiology of OA and provide a necessary 
step in pre-clinical investigations of potential therapeutic strategies. A number of animal OA models have 
now been established including the MIA model. To date, the potential systemic influences of MIA in this 
model have not been fully investigated. Despite assuming that there are relatively low circulating 
concentrations of MIA, the deleterious effects to surrounding musculoskeletal tissues are yet to be 
investigated and hence the influence on the phenotypic outcome is currently unknown.  
Here we sought to determine the effects of MIA on skeletal muscle cells and have used an in vitro model to 
demonstrate significant myogenic effects. Responses observed at early time-points were similar to that 
previously reported with DEX treatment; reduced differentiation and an apparent rapid atrophic phenotype 
[15,16]. Myotube width analyses confirmed a hypertrophic phenotype in CON compared to MIA and DEX, 
however, only with DEX treatment was there an observed increase in MAFbx mRNA, supporting previous 
findings for its atrophic role in this condition [17].  
It is important to consider however the delayed differentiation and hyperplasic phenotype in both MIA and 
DEX conditions at the later time-points, a phenotype suggested to be regulated by myogenic regulatory factors 
(MRF’s) myoD and myogenin [18]. This hyperplasic response, along with the apparent increases in fusion 
efficiency at 48hrs in DEX and MIA compared to CON, would suggest that both treatment conditions have 
the ability to stimulate and potentially augment myogenesis, albeit in a delayed capacity. An increased 
differentiation and hypertrophic capacity of C2C12’s treated with DEX when co-incubated with IGF-I, has 
previously been reported [19]. This is thought to occur through the IGF-I-meditated translation of 
accumulated muscle-specific mRNA transcripts induced by DEX [19] and may in part explain the delayed, yet 
augmented hyperplasic phenotype observed in the DEX condition presented here.  
Despite similar morphological findings between MIA and DEX conditions, the primary activated mechanisms 
which contribute to this shared phenotype are potentially distinct. DEX-mediated skeletal muscle atrophy is 
thought to occur through the initiation of mechanisms regulating protein breakdown. Specifically, increases in 
MuRF1 and MAFbx mRNA’s following DEX has been attributed to the activation of FOXO1 and FOXO3A, 
as a result of reduced Akt activity [17]. The mechanism regulating the hyperplasic and reduced myotube 
width phenotype observed in the MIA condition is currently unknown, however given the glycolytic 
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inhibitory capacity of MIA, it could be speculated that this response is a consequence of disrupted cellular 
energy status. Increases in AMPK activity as a consequence of an augmented AMP-to-ATP ratio, has been 
shown to inhibit mTOR, through the phosphorylation of TSC2 [20], inhibiting the key mechanism for protein 
synthesis and hence reducing the ability for the differentiated myotubes to hypertrophy.   
The interaction between cartilage and skeletal muscle tissue in OA pathology is critical to the development of 
reproducible pre-clinical models. In vivo, primary cartilage degradation contributes to significant 
biomechanical changes and is thought to affect skeletal muscle through pain and limb unloading mechanisms 
contributing to fibre atrophy and subsequent weakness. Reduced myogenic regeneration and inhibition of 
skeletal muscle hypertrophy observed in this work indicates that should MIA become systemic, deleterious 
effects on the surrounding tissue may well be apparent and significant.  
5. Conclusions 
We have demonstrated significant myogenic effects of MIA in an isolated in vitro model, similar to that seen 
in DEX. Future work should seek to determine if MIA administration affects skeletal muscle regeneration and 
hypertrophy in vivo and in particular whether such potential negative outcomes, contribute to the development 
of the observed OA phenotype. This will need to be investigated using an integrated approach of in vivo 
testing of muscle function and a raft of ex vivo analyses to understand any impact at the functional and 
molecular levels respectively.   
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